Latest Adult attention deficit hyperactivity disorder Stories
PHILADELPHIA, July 28 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has received a Complete Response letter today for INTUNIV(TM) (guanfacine) Extended Release from the Food and Drug Administration (FDA). This decision comes following labeling discussions with the FDA that did not result in agreement in time to meet the PDUFA date. The FDA did not identify safety concerns regarding INTUNIV in the Complete...
22nd Congress of the European College of Neuropsychopharmacology (ECNP), 12 - 16 September 2009, Istanbul, Turkey
-- Missing DNA Segments May Suggest Future Drug Targets -- PHILADELPHIA, June 23 /PRNewswire-USNewswire/ -- Pediatric researchers have identified hundreds of gene variations that occur more frequently in children with attention-deficit hyperactivity disorder (ADHD) than in children without ADHD.
Pediatric researchers have identified hundreds of gene variations that occur more frequently in children with attention-deficit hyperactivity disorder (ADHD) than in children without ADHD.
More than five million Americans currently take medication to manage their symptoms of attention deficit disorder. Yet untold millions remain undiagnosed and untreated for ADHD - partially because the process can be so daunting.
TITUSVILLE, N.J., April 22 /PRNewswire/ -- Although Attention Deficit Hyperactivity Disorder (ADHD) is a condition commonly thought of as only affecting children, for nearly 9 million adults in the United States, ADHD is very much a reality.
RESEARCH TRIANGLE PARK, N.C., March 31 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (NYSE: GSK) has entered into a co-promotion agreement with Shire plc (LSE: SHP, Nasdaq: SHPGY) for Vyvanse(R), to help improve the recognition and treatment of adult Attention Deficit Hyperactivity Disorder (ADHD).
PHILADELPHIA, March 31 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced a co-promotion agreement with GlaxoSmithKline plc (NYSE: GSK) for VYVANSE(R) (lisdexamfetamine dimesylate) capsules CII with the aim of improving recognition and treatment of ADHD in adults.
A new University of Central Florida study may explain why children with attention deficit hyperactivity disorder move around a lot â€“ it helps them stay alert enough to complete challenging tasks.
- totally perplexed and mixed up.